Logo

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Share this

Novartis Signs an Option and License Agreement with Molecular Partners to Develop Two DARPin Therapies for COVID-19

Shots:

  • Molecular Partners to receive $65.8M as up front- including equity- and will receive $164.7M as an option payment for both MP0420 and MP0423 along with royalties on sales of therapies. Novartis to get an option to in-license global rights of MP0420 and MP0423
  • During the option period- Molecular Partners will conduct a P-I study for MP0420- expected to initiate in Nov’2020- and perform all remaining preclinical work for MP0423 while Novartis will lead P-II & P-III study
  • Upon option exercise- Novartis will lead further development and commercialization activities while Molecular Partners will provide clinical supply during the development stage. MP0420 and MP0423 are potential medicines for the prevention & treatment of COVID-19- with the possibility of being manufactured at scale and the potential to bypass cold storage

 ­ Ref: Novartis | Image: Novartis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions